Karyopharm reports first quarter 2024 financial results and highlights recent company progress

– announces significant refinancing transactions and amends royalty agreement with healthcare royalty extending vast majority of its debt maturities into 2028 and 2029, well beyond expected data readouts and potential approvals from the company's three phase 3 trials, strengthening the company for its next stage of growth –  – achieves first quarter 2024 total revenue of $33.1 million and u.s. xpovio® (selinexor) net product revenue of $26.0 million – –  reaffirms full year 2024 total revenue guidance of $140 .0  million to $160 .0  million, including u.s. xpovio net product revenue guidance of $100 .0  million to $120 .0  million – –        invited to present updated data from a pre-specified exploratory subgroup analysis of the phase 3 siendo trial of selinexor maintenance treatment in patients with tp53 wild-type advanced/recurrent endometrial cancer at 2024 asco annual meeting – – conference call scheduled for today at 8:00 a.m. et – newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking